According to an AstraZeneca representative, the AZD1222 vaccine candidate contains the genetic material of the SARS-CoV-2 virus spike protein, and the changes in the genetic code of the new strain do not affect the structure of the spike protein. Drug manufacturers are rushing to test their COVID-19 vaccines against the highly contagious new variant of the virus spreading in Britain. The vaccination with AZD1222 helps the immune system recognize various parts of the spike protein to eliminate the virus if exposed later. The mutation, known as the B.1.1.7 lineage, is believed to be up to 70% more infectious and poses a greater risk to children. This has caused chaos in Britain, leading to travel bans, disrupting trade with Europe, and potentially isolating the island country further. The AstraZeneca-Oxford vaccine is seen as important for countries with lower incomes and hot climates due to its affordability, ease of transportation, and ability to be stored at regular refrigerator temperatures for extended periods. Recent data from AstraZeneca's trials in the UK and Brazil revealed varying levels of efficacy, with the vaccine showing 62% efficacy for those given two full doses and 90% for a smaller group given a half dose followed by a full dose. India is expected to approve the vaccine for emergency use by next week, according to Reuters.